Results 231 to 240 of about 1,084,074 (266)
Some of the next articles are maybe not open access.
The affinity of human RANK binding to its ligand RANKL
Archives of Biochemistry and Biophysics, 2009Receptor activator of nuclear factor-kappa B (RANK) and its ligand, RANKL play critical roles in bone re-modeling, immune function, vascular disease and mammary gland development. To study the interaction of RANK and RANKL, we have expressed both extracellular domain of RANK and ectodomain of RANKL using Escherichia coli expression system.
Shu Zhou, Jingshan Ren, Zhenggang Bi
exaly +3 more sources
The International Journal of Biochemistry & Cell Biology, 2007
RANK ligand (RANKL), a key mediator of bone resorption in normal and pathological states, is expressed as membrane-bound or soluble forms by tissues as diverse as lymph nodes, spleen, thymus and bone-forming cells. In normal bone turnover and in bone metastasis, RANKL stimulates the formation and activity of bone-removing cells, osteoclasts, by binding
J M, Blair, Y, Zheng, C R, Dunstan
openaire +2 more sources
RANK ligand (RANKL), a key mediator of bone resorption in normal and pathological states, is expressed as membrane-bound or soluble forms by tissues as diverse as lymph nodes, spleen, thymus and bone-forming cells. In normal bone turnover and in bone metastasis, RANKL stimulates the formation and activity of bone-removing cells, osteoclasts, by binding
J M, Blair, Y, Zheng, C R, Dunstan
openaire +2 more sources
Ranking the role of RANK ligand in apoptosis
Apoptosis, 2004Many members of tumor necrosis factor (TNF) superfamily are characterized by their ability to induce apoptosis once they bind in a homotrimeric manner to their cognate receptors. The receptor activator of nuclear factor-kappaB ligand (RANKL), a member of the TNF superfamily identified seven years ago, was originally described as a factor that induced ...
A C, Bharti, B B, Aggarwal
openaire +2 more sources
Osteoprotegerin and rank ligand expression in prostate cancer
Urology, 2001To investigate the expression of osteoprotegerin (OPG) and RANK ligand (RANKL) in human prostatic tissues. The factors regulating the increased turnover associated with prostate cancer (CaP) bone metastasis are unknown. OPG and RANKL are recently identified regulators of bone resorption and bone remodeling.Tissues from 28 patients with CaP and from 4 ...
J M, Brown +6 more
openaire +2 more sources
Clinical applications of RANK‐ligand inhibition
Internal Medicine Journal, 2009AbstractAn enhanced rate of bone remodelling fuelled by osteoclastogenesis mediates diseases such as osteoporosis, arthritic bone destruction, Paget’s disease and malignancy‐induced bone loss. Thus, the control of osteoclastogenesis is of major clinical importance.
openaire +2 more sources
RANK ligand and osteoprotegerin in myeloma bone disease
Blood, 2003Myeloma bone disease is due to interactions of myeloma cells with the bone marrow microenvironment, and is associated with pathologic fractures, neurologic symptoms and hypercalcemia. Adjacent to myeloma cells, the formation and activation of osteoclasts is increased, which results in enhanced bone resorption.
Orhan, Sezer +4 more
openaire +2 more sources
Bone, 2009
Orchiectomized (ORX) rats were used to examine the extent to which their increased bone resorption and decreased bone density might relate to increases in RANKL, an essential cytokine for bone resorption.
Xiaodong, Li +13 more
openaire +2 more sources
Orchiectomized (ORX) rats were used to examine the extent to which their increased bone resorption and decreased bone density might relate to increases in RANKL, an essential cytokine for bone resorption.
Xiaodong, Li +13 more
openaire +2 more sources
Bone, 2012
increased fracture risk occur early after therapy is initiated, emphasising the importance of primary prevention of fracture in high-risk individuals. Most currently available guidelines for the management of GIO were developed prior to the release of FRAX® and other risk assessment tools and the approval of newer pharmacological interventions for its ...
openaire +1 more source
increased fracture risk occur early after therapy is initiated, emphasising the importance of primary prevention of fracture in high-risk individuals. Most currently available guidelines for the management of GIO were developed prior to the release of FRAX® and other risk assessment tools and the approval of newer pharmacological interventions for its ...
openaire +1 more source
Osteoprotegerin, rank and rank ligand
2007The discovery of the osteoprotegerin, receptor activator of nuclear factor-kappa B ligand and receptor activator of nuclear factor-kappa B and identification of their role in osteoclastogenesis provided a major advance in bone biology. receptor activator of nuclear factor-kappa B ligand binds to its receptors on the surface of preosteoclasts and ...
Kurban, Sevil, Mehmetoglu, Idris
openaire +1 more source
Expression of RANK‐ligand in prostate cancer cell lines
Scandinavian Journal of Clinical and Laboratory Investigation, 2009The molecular mediators of bone remodelling, receptor activator of nuclear factor-kappaB ligand (RANKL), receptor activator of nuclear factor-kappaB (RANK) and osteoprotegerine (OPG), are believed to be involved in the cellular mechanisms by which tumours metastasize to bone. RANKL is a potent stimulator of osteoclastic bone resorption and is expressed
Hendrik, Penno +4 more
openaire +2 more sources